Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures

Epilepsia

Volumn 45, Issue 6, 2004, Pages 610-617

  Sackellares, J Chris ^a,e   Ramsay, R Eugene ^b   Wilder, B Joseph ^a   Browne III, Thomas R ^c   Shellenberger, M Kent ^d  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c BOSTON UNIVERSITY   (United States)

^d ELAN PHARMACEUTICALS   (United States)

^e UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Antiepilepsy drug; Epilepsy; Partial onset seizures; Randomized controlled trial; Zonisamide

Indexed keywords

PLACEBO; ZONISAMIDE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLECYSTITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOCAL EPILEPSY; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OBSTRUCTIVE JAUNDICE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; TACHYCARDIA; THROMBOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; HEALTH STATUS; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME;

EID: 3042636758     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0013-9580.2004.11403.x     Document Type: Article

References (17)

1. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987;413:185-8.
2. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992;12:21-7.
3. +, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol 1998;124:1277-85.
4. Zhu W, Rogawski A. Zonisamide depresses excitatory synaptic transmission by a presynaptic action [Abstract]. Epilepsia 1999;40:245.
5. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995;22:193-205.
6. Okada M, Hirano T, Kawata Y, et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res 1999;34:187-97.
7. Komatsu M, Okamura Y, Hiramatsu M. Free radical scavenging activity of zonisamide and its inhibitory effect on lipid peroxide formation in iron-induced epileptogenic foci of rats. Neurosciences 1995;21:23-9.
8. Mori A, Noda Y, Packer L. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res 1998;30:153-8.
9. Kawai M, Endoh A, Kinno I, et al. Effect of zonisamide on release of aspartic acid and gamma-aminobutyric acid from the hippocampal slices of E1 mice. Neurosciences 1994;20:115-9.
10. Endoh A, Kinno I, Kawai M, et al. Effect of zonisamide on neurotransmitter in mouse brain. Neurosciences 1994;20:P173-6.
11. Masuda Y, Karasawa T. Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneimittelforschung 1993;43: 416-8.
12. Sackellares JC, Donofrio PD, Wagner JG, et al. Pilot study of zonisamide (1.2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures. Epilepsia 1985;26:206-11.
13. Leppik IE, Willmore LJ, Homan RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993;14:165-73.
14. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993;15:67-73.
15. Yagi K, Seino M. Methodological requirements for clinical trials in refractory epilepsies: our experience with zonisamide. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:79-85.
16. Faught E, Ayala R, Montouris GG, et al. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001;57:1774-9.
17. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276:637-9.